Advertisement


Lisa A. Carey, MD, and Maki Tanioka, MD, on HER2+ Breast Cancer: Results From the CALGB 40601 Alliance Trial

2016 San Antonio Breast Cancer Symposium

Advertisement

Lisa A. Carey, MD, and Maki Tanioka, MD, both of the University of North Carolina, discuss study findings on weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer (Abstract S3-05).



Related Videos

Breast Cancer

Sonja Vliek, MD, and Sabine Linn, MD, PhD, on Early Breast Cancer: Results of the TEAM IIb Trial

Sabine Linn, MD, PhD, and Sonja Vliek, MD, both of the Netherlands Cancer Institute, discuss study findings on adjuvant ibandronate in postmenopausal women with early...

Breast Cancer

Ruth O'Regan, MD, on Locally Advanced and Metastatic Breast Cancer: Results of the BELLE-3 Trial

Ruth O'Regan, MD, of the University of Wisconsin, discusses study findings on buparlisib plus fulvestrant in postmenopausal women with HR-positive, HER2-positive, aromatase inhibitor–...

Breast Cancer
Survivorship

Dawn Hershman, MD, on Breast Cancer Survivorship: Poster Discussion

Dawn Hershman, MD, of the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, reviews findings on survivorship care plans, interventions to reduce chemot...

Breast Cancer

Samuel Smith, PhD, on Tamoxifen Adherence: Results of the IBIS-1 Study

Samuel Smith, PhD, of Queen Mary University of London, discusses study findings on menopausal symptoms as predictors of long‐term adherence in an International breast cancer intervent...

Breast Cancer

Aleix Prat, MD, PhD, on HER2-Positive Breast Cancer: First Results of the PAMELA Trial

Aleix Prat, MD, PhD, of the University of Barcelona, discusses study findings on intrinsic subtype as a predictor of pathologic complete response following neoadjuvant dual HER2 block...

Advertisement

Advertisement



;
Advertisement